Regulation of Resistance Against Adjuvant Arthritis in the Fisher Rat

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 1993 Oct 1

PMID 8403498

Citations 4

Authors

A G van de Langerijt

P L van Lent

A R Hermus

L B van de Putte

W B van den Berg

Affiliations

Soon will be listed here.

Abstract

Inbred female Lewis (LEW/N) rats develop a severe chronic arthritis in the adjuvant arthritis (AA) model, histocompatible Fisher (F344/N) rats are resistant and germ-free Fishers (GF F344) are again susceptible. In this study we show that the F344 rat can become susceptible to AA, using Mycobacterium tuberculosis (M.tb.) in the powerful adjuvant paraffin oil, instead of mineral oil (Freund's incomplete adjuvant (FIA)). This indicates that the F344 rat does not lack T effector cells. To examine further mechanisms responsible for suppression, we determined the level of plasma corticosterone in response to IL-1 alpha in Lewis, F344 and GF F344 rats. IL-1 alpha induced only low amounts of corticosterone in Lewis rats, but high amounts in both F344 and GF F344 rats. The GF F344 rats are susceptible to AA, but the severity of the disease is reduced compared with Lewis rats. This indicates that corticosterone may be an important mechanism to suppress disease development, but not the only mechanism. In addition we investigated whether T suppressor cells play a role in the resistance of the F344 strain. This was performed by pretreating the animals with the immunomodulating drugs cyclophosphamide (Cy) and cyclosporin A (CsA). We were unable to make the F344 rat susceptible to AA, indicating that active suppression does not play a role in the induction phase of arthritis. This finding is confirmed in adoptive transfer experiments of AA from Lewis to F344 rats. Our data suggest the lack of a strong pre-existing suppression in the F344 rats, and indicate that suppression is generated upon bacterial challenge. Whether suppression is overruled probably depends on the power of adjuvants used and potential control by corticosteroids.

Citing Articles

The determinants of susceptibility/resistance to adjuvant arthritis in rats.

Kim E, Moudgil K Arthritis Res Ther. 2009; 11(4):239.

PMID: 19678912 PMC: 2745784. DOI: 10.1186/ar2755.

Microbial considerations in genetically engineered mouse research.

Franklin C ILAR J. 2006; 47(2):141-55.

PMID: 16547371 PMC: 7108594. DOI: 10.1093/ilar.47.2.141.

A role for mast cells in the development of adjuvant-induced vasculitis and arthritis.

Johnston B, Burns A, Kubes P Am J Pathol. 1998; 152(2):555-63.

PMID: 9466582 PMC: 1857978.

Susceptibility to adjuvant arthritis: relative importance of adrenal activity and bacterial flora.

van de Langerijt A, van Lent P, Hermus A, Sweep C, Cools A, van den Berg W Clin Exp Immunol. 1994; 97(1):33-8.

PMID: 8033416 PMC: 1534789. DOI: 10.1111/j.1365-2249.1994.tb06575.x.

References

Altmann D, Blyth W . The effects of cyclosporin A on the induction, expression and regulation of the immune response to herpes simplex virus. Clin Exp Immunol. 1985; 59(1):17-22. PMC: 1577171. View

Wilder R, Calandra G, Garvin A, Wright K, Hansen C . Strain and sex variation in the susceptibility to streptococcal cell wall-induced polyarthritis in the rat. Arthritis Rheum. 1982; 25(9):1064-72. DOI: 10.1002/art.1780250906. View

Sweep C, van der Meer M, Hermus A, Smals A, van der Meer J, Pesman G . Chronic stimulation of the pituitary-adrenal axis in rats by interleukin-1 beta infusion: in vivo and in vitro studies. Endocrinology. 1992; 130(3):1153-64. DOI: 10.1210/endo.130.3.1311230. View

CROMARTIE W, CRADDOCK J, Schwab J, ANDERLE S, Yang C . Arthritis in rats after systemic injection of streptococcal cells or cell walls. J Exp Med. 1977; 146(6):1585-602. PMC: 2181919. DOI: 10.1084/jem.146.6.1585. View

Polman C, Matthaei I, de Groot C, Koetsier J, Sminia T, Dijkstra C . Low-dose cyclosporin A induces relapsing remitting experimental allergic encephalomyelitis in the Lewis rat. J Neuroimmunol. 1988; 17(3):209-16. DOI: 10.1016/0165-5728(88)90069-0. View

Taurog J, Sandberg G, Mahowald M . The cellular basis of adjuvant arthritis. I. Enhancement of cell-mediated passive transfer by concanavalin A and by immunosuppressive pretreatment of the recipient. Cell Immunol. 1983; 75(2):271-82. DOI: 10.1016/0008-8749(83)90325-8. View

Sedgwick J . Long-term depletion of CD8+ T cells in vivo in the rat: no observed role for CD8+ (cytotoxic/suppressor) cells in the immunoregulation of experimental allergic encephalomyelitis. Eur J Immunol. 1988; 18(4):495-502. DOI: 10.1002/eji.1830180402. View

Askenase P, Hayden B, GERSHON R . Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses. J Exp Med. 1975; 141(3):697-702. PMC: 2189708. DOI: 10.1084/jem.141.3.697. View

Billingham M, Carney S, Butler R, Colston M . A mycobacterial 65-kD heat shock protein induces antigen-specific suppression of adjuvant arthritis, but is not itself arthritogenic. J Exp Med. 1990; 171(1):339-44. PMC: 2187658. DOI: 10.1084/jem.171.1.339. View

10.

Currey H . A comparison of immunosuppressive and anti-inflammatory agents in the rat. Clin Exp Immunol. 1971; 9(6):879-87. PMC: 1713123. View

11.

Mosmann T, Coffman R . TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989; 7:145-73. DOI: 10.1146/annurev.iy.07.040189.001045. View

12.

BATTISTO J, Smith R, Beckman K, STERNLICHT M, Welles W . Susceptibility to adjuvant arthritis in DA and F344 rats. A dominant trait controlled by an autosomal gene locus linked to the major histocompatibility complex. Arthritis Rheum. 1982; 25(10):1194-200. DOI: 10.1002/art.1780251008. View

13.

Billingham M, Hicks C, Carney S . Monoclonal antibodies and arthritis. Agents Actions. 1990; 29(1-2):77-87. DOI: 10.1007/BF01964727. View

14.

Sternberg E, Hill J, Chrousos G, Kamilaris T, Listwak S, Gold P . Inflammatory mediator-induced hypothalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis-susceptible Lewis rats. Proc Natl Acad Sci U S A. 1989; 86(7):2374-8. PMC: 286915. DOI: 10.1073/pnas.86.7.2374. View

15.

Chang Y, Pearson C, Abe C . Adjuvant polyarthritis. IV. Induction by a synthetic adjuvant: immunologic, histopathologic, and other studies. Arthritis Rheum. 1980; 23(1):62-71. DOI: 10.1002/art.1780230111. View

16.

Pearson C . Development of arthritis, periarthritis and periostitis in rats given adjuvants. Proc Soc Exp Biol Med. 1956; 91(1):95-101. DOI: 10.3181/00379727-91-22179. View

17.

Kayashima K, Koga T, Onoue K . Role of T lymphocytes in adjuvant arthritis. II. Different subpopulations of T lymphocytes functioning in the development of the disease. J Immunol. 1978; 120(4):1127-31. View

18.

Borel J, Feurer C, GUBLER H, STAHELIN H . Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions. 1976; 6(4):468-75. DOI: 10.1007/BF01973261. View

19.

Larsson P, Holmdahl R, Dencker L, Klareskog L . In vivo treatment with W3/13 (anti-pan T) but not with OX8 (anti-suppressor/cytotoxic T) monoclonal antibodies impedes the development of adjuvant arthritis in rats. Immunology. 1985; 56(3):383-91. PMC: 1453748. View

20.

Kaibara N, Hotokebuchi T, Takagishi K, Katsuki I, Morinaga M, Arita C . Pathogenetic difference between collagen arthritis and adjuvant arthritis. J Exp Med. 1984; 159(5):1388-96. PMC: 2187290. DOI: 10.1084/jem.159.5.1388. View